Difference in mesothelin‐binding ability of serum CA125 between patients with endometriosis and epithelial ovarian cancer

Sasaki A, Aya Sasaki, Akita K, Kaoru Akita, Fumitake Ito, Ito F, Mori T, Taisuke Mori, Kitawaki J, Jo Kitawaki, Nakada H, Hiroshi Nakada
International journal of cancer · 2014 · vol. 136(8) , pp. 1985–1990 · doi:10.1002/ijc.29185 · PMID:25197000 · W1883005803
article OA: bronze CC0 ⤵ 4 in-corpus citations
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-12 ⓘ

A novel ELISA measuring mesothelin-binding ability of serum CA125 found significantly higher levels and ratios in epithelial ovarian cancer patients compared to endometriosis patients, improving differential diagnosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The epithelial ovarian carcinoma (EOC) is an aggressive malignant tumor, and is currently the leading cause of gynecologic cancer death. CA125 is the most commonly used serum marker for EOC, but shows a high-false-positive rate for several benign diseases such as endometriosis. The purpose of our study is therefore to identify a useful biochemical tool for detecting qualitative differences between CA125 from patients with endometriosis and EOC, and to facilitate differential diagnosis of these diseases. In our study, using two different CA125-binding molecules, i.e., recombinant mesothelin and an anti-CA125 monoclonal antibody, a novel sandwich ELISA for determining the serum levels of CA125 with mesothelin-binding ability (CA125(meso) ) was developed, and tested for patients with endometriosis (n = 59) and EOC (n = 36). We found that both the serum CA125(meso) level and the ratio of the serum CA125(meso) to CA125 levels (CA125(meso) /CA125) were significantly higher in patients with EOC than in patients with endometriosis (p < 0.00005 and p < 0.000001, respectively). Furthermore, receiver operating characteristic analysis showed that the CA125(meso) assay was superior to the conventional antibody-based CA125 assay in discriminating endometriosis from EOC. Thus, mesothelin-binding ability may be a useful indicator for qualitatively evaluating CA125 in patients with endometriosis and EOC.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

CA-125 Antigen CA-125 Antigen Endometriosis Endometriosis GPI-Linked Proteins Neoplasms, Glandular and Epithelial Neoplasms, Glandular and Epithelial Ovarian Neoplasms Ovarian Neoplasms Adult Aged Aged, 80 and over Biomarkers, Tumor Biomarkers, Tumor Biomarkers, Tumor CA-125 Antigen Carcinoma, Ovarian Epithelial Endometriosis Female GPI-Linked Proteins

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

Cited by (4)

References (25)

Cited by (4)

Source provenance

europepmc
last seen: 2026-09-03T06:15:13.668130+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:18:15.805398+00:00
License: CC0 · commercial use OK